Signant Health Brand Guidelines: CRF Health, Bracket & the 2019 Rename

Two clinical-trial businesses and a 2019 rename.

Signant Health is a clinical-trial technology company built from two older businesses. On 10 June 2019, a press release datelined London and Philadelphia announced that CRF Bracket, “formed by the 2018 merger of CRF Health and Bracket,” had launched under the new name Signant Health. Clinical Research News reported the same day that the two companies had been joined in July 2018, when the investment firm Genstar Capital, then the owner of Bracket, acquired CRF Health, and that the combined business had traded as CRF Bracket in the months between.

The company’s own timeline takes the story further back. It says CRF Health, formerly known as CRF Inc., was founded in 2000, and that PharmaStar LLC, the predecessor of Bracket Global, was founded in 2001. Bracket itself, the company says, was created in 2011 by merging two business units — Specialty Clinical Services and the Clinical Technologies Group — inside United BioSource Corporation. In 2017, according to the same timeline and to Clinical Research News, Bracket acquired mProve Health, a patient-engagement business whose tools Signant went on to build on.

The new name was explained at launch. “The new Signant brand reflects our desire to help separate signal from noise at the intersection of science and technology,” the chief executive, Mike Nolte, said in the release, adding that customers’ “significant work matters locally and globally.” Nolte told Clinical Research News that the new name was “more indicative of the kind of business we’re trying to build,” and joked that a rebrand was not something he hoped to repeat. The release said the new identity would go online on launch day and be rolled out fully at the DIA Global Annual Meeting later that month, the industry’s large yearly gathering for drug-development professionals.

eCOA, eConsent, IRT and endpoint quality.

At the rename, Clinical Research News noted, the products themselves had not changed. The new website still listed TrialConsent and TrialMax, which came from CRF Health, alongside SmartSupplies and Rater Station from Bracket. Together they covered what the industry calls eCOA — electronic clinical outcome assessment, in which patients and clinicians record trial data on phones, tablets or the web — as well as eConsent, patient engagement, IRT (the interactive response technology used to randomise patients and manage trial supplies), clinical supplies and what the company called endpoint quality. Rater Station, the article said, had been designed for use in neuroscience studies, and the company was working to shorten the time it took to set up.

Nolte framed the merger around patients. When the two companies combined, he told Clinical Research News, they saw a chance to stand apart “around a very patient-centric strategy,” and the stated goal of the renamed business was to make clinical trials easier to take part in and to run. He also described ideas the company was exploring, such as turning the eCOA device in a patient’s home into a hub rather than only a tool for collecting data.

The business has added to that base since. In July 2023, Applied Clinical Trials reported that Signant had acquired DSG, a provider of electronic data capture and direct data capture technology described as about 20 years old, which would become “a Signant company.” The company’s timeline also lists the purchase of VirTrial in 2020, to support research sites digitally; the launch of Signant Biotech, a package aimed at small and mid-sized drug developers, in 2023; and an AI support assistant called SHAI in 2025.

In June 2026, Investors in Healthcare reported that the Genstar-backed company had acquired Ametris, formerly ActiGraph, a digital health company, from the investor Archimed. Signant says the deal adds sensor-based biomarker data to the patient-reported information its software already gathers.

How the category presents itself.

Life-sciences software is sold to scientists, clinicians, regulators and procurement teams at once, and the way these companies present themselves reflects that mixed audience. Their websites and brochures tend to show clean dashboards on laptops and tablets, molecule renderings and data charts, and people in lab coats or at clinic desks looking at screens. The product, in other words, is usually shown as an interface rather than an object.

The colour schemes follow the same logic. Many of these brands set one or two bright product colours against a lot of white space, so that charts, buttons and status labels stand out, and they use plain sans-serif type that stays legible in dense tables. Product families are often split into named “clouds,” “suites” or “platforms,” each with its own sub-brand, so a single company can carry dozens of product names under one mark.

Much of the selling happens in person. The sector gathers at trade conferences such as the DIA Global Annual Meeting, which brings together people working on drug development and regulation; Bio-IT World, which focuses on data and computing in life-sciences research; and SLAS, the laboratory-automation and screening society’s conference. Larger vendors also run their own customer summits, with keynote stages, product launches and user sessions; Medidata, for example, says its NEXT conference grew out of a user group for its Rave software.

Ownership matters too: several of the companies in this round have changed hands, and some have been bought by larger groups while keeping their own names. The guides in this round set out who founded each company, who owns it now and what it makes, and they mark clearly which statements rest only on the company’s own word.

A name built around a signal.

Signant’s name is the centre of its brand story, and later product names keep returning to it. The website describes a SmartSignals ecosystem and a connected environment for trial data called SignalSpace, and it now presents the business under the trademarked line “The Evidence Generation Company.” The 2019 launch release opened its company description with a line credited to Nolte: “The best technology in clinical research succeeds in the background.”

The company works across two continents. Its website lists offices in Blue Bell and Horsham, Pennsylvania, and in Europe in Helsinki, Iasi in Romania, Milton Keynes and Dublin, among others; its 2019 launch release was datelined London and Philadelphia. It remains privately owned: Genstar Capital, which brought the two companies together in 2018, was still named as its backer by Investors in Healthcare in 2026. Leadership has changed since the rename — by July 2023, Applied Clinical Trials quoted Roger Smith as Signant’s chief executive, welcoming the DSG team.

For a design guide, Signant Health shows how a merged company can pick a new name that explains itself — a word about finding the signal in data — and then build its product names around it. Compare Clario, another clinical-trial technology company, and Medidata, another maker of clinical-trial software. For this guide we use a deep indigo, a coral and a pale mist with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Signant Health’s identity on hand — save it to a board in the Made Good inspiration library.